Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

PKM2 enhances chemosensitivity to cisplatin through interaction with the mTOR pathway in cervical cancer.

Zhu H, Wu J, Zhang W, Luo H, Shen Z, Cheng H, Zhu X.

Sci Rep. 2016 Aug 5;6:30788. doi: 10.1038/srep30788.

2.

Reducing Both Pgp Overexpression and Drug Efflux with Anti-Cancer Gold-Paclitaxel Nanoconjugates.

Li F, Zhou X, Zhou H, Jia J, Li L, Zhai S, Yan B.

PLoS One. 2016 Jul 28;11(7):e0160042. doi: 10.1371/journal.pone.0160042. eCollection 2016.

3.

Knockdown of long noncoding RNA H19 sensitizes human glioma cells to temozolomide therapy.

Jiang P, Wang P, Sun X, Yuan Z, Zhan R, Ma X, Li W.

Onco Targets Ther. 2016 Jun 13;9:3501-9. doi: 10.2147/OTT.S96278. eCollection 2016.

4.

Molecular mechanisms of cisplatin resistance in cervical cancer.

Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X.

Drug Des Devel Ther. 2016 Jun 7;10:1885-95. doi: 10.2147/DDDT.S106412. eCollection 2016. Review.

5.

Crocin suppresses multidrug resistance in MRP overexpressing ovarian cancer cell line.

Mahdizadeh S, Karimi G, Behravan J, Arabzadeh S, Lage H, Kalalinia F.

Daru. 2016 Jun 24;24(1):17. doi: 10.1186/s40199-016-0155-8.

6.

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer.

Zheng ZG, Xu H, Suo SS, Xu XL, Ni MW, Gu LH, Chen W, Wang LY, Zhao Y, Tian B, Hua YJ.

Sci Rep. 2016 May 19;6:26093. doi: 10.1038/srep26093.

7.

Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer.

Andorfer P, Heuwieser A, Heinzel A, Lukas A, Mayer B, Perco P.

BMC Syst Biol. 2016 Apr 18;10:33. doi: 10.1186/s12918-016-0278-z.

8.

A phosphotyrosine switch regulates organic cation transporters.

Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N.

Nat Commun. 2016 Mar 16;7:10880. doi: 10.1038/ncomms10880.

9.

Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment.

Kang L, Gao Z, Huang W, Jin M, Wang Q.

Acta Pharm Sin B. 2015 May;5(3):169-75. doi: 10.1016/j.apsb.2015.03.001. Epub 2015 Apr 8. Review.

10.

Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR, Heger M.

Cancer Metastasis Rev. 2015 Dec;34(4):643-90. doi: 10.1007/s10555-015-9588-7.

11.

Altered Gene Expression in the Schistosome-Transmitting Snail Biomphalaria glabrata following Exposure to Niclosamide, the Active Ingredient in the Widely Used Molluscicide Bayluscide.

Zhang SM, Buddenborg SK, Adema CM, Sullivan JT, Loker ES.

PLoS Negl Trop Dis. 2015 Oct 9;9(10):e0004131. doi: 10.1371/journal.pntd.0004131. eCollection 2015.

12.

Role of MRP transporters in regulating antimicrobial drug inefficacy and oxidative stress-induced pathogenesis during HIV-1 and TB infections.

Roy U, Barber P, Tse-Dinh YC, Batrakova EV, Mondal D, Nair M.

Front Microbiol. 2015 Sep 17;6:948. doi: 10.3389/fmicb.2015.00948. eCollection 2015. Review.

13.

The complexity of the Nrf2 pathway: beyond the antioxidant response.

Huang Y, Li W, Su ZY, Kong AN.

J Nutr Biochem. 2015 Dec;26(12):1401-13. doi: 10.1016/j.jnutbio.2015.08.001. Epub 2015 Aug 8. Review.

PMID:
26419687
14.

A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.

Delaney JR, Patel C, McCabe KE, Lu D, Davis MA, Tancioni I, von Schalscha T, Bartakova A, Haft C, Schlaepfer DD, Stupack DG.

Oncotarget. 2015 Oct 13;6(31):31104-18. doi: 10.18632/oncotarget.5093.

15.

Multidrug ATP-binding cassette transporters are essential for hepatic development of Plasmodium sporozoites.

Rijpma SR, van der Velden M, González-Pons M, Annoura T, van Schaijk BC, van Gemert GJ, van den Heuvel JJ, Ramesar J, Chevalley-Maurel S, Ploemen IH, Khan SM, Franetich JF, Mazier D, de Wilt JH, Serrano AE, Russel FG, Janse CJ, Sauerwein RW, Koenderink JB, Franke-Fayard BM.

Cell Microbiol. 2016 Mar;18(3):369-83. doi: 10.1111/cmi.12517. Epub 2015 Nov 10.

PMID:
26332724
16.
17.

Multidrug resistance characterization in multicellular tumour spheroids from two human lung cancer cell lines.

Barrera-Rodríguez R, Fuentes JM.

Cancer Cell Int. 2015 Apr 24;15:47. doi: 10.1186/s12935-015-0200-6. eCollection 2015.

18.

Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.

Mo L, Pospichalova V, Huang Z, Murphy SK, Payne S, Wang F, Kennedy M, Cianciolo GJ, Bryja V, Pizzo SV, Bachelder RE.

PLoS One. 2015 Jul 6;10(7):e0131579. doi: 10.1371/journal.pone.0131579. eCollection 2015.

19.

Suppression of MAPK Signaling and Reversal of mTOR-Dependent MDR1-Associated Multidrug Resistance by 21α-Methylmelianodiol in Lung Cancer Cells.

Aldonza MB, Hong JY, Bae SY, Song J, Kim WK, Oh J, Shin Y, Lee SH, Lee SK.

PLoS One. 2015 Jun 22;10(6):e0127841. doi: 10.1371/journal.pone.0127841. eCollection 2015. Erratum in: PLoS One. 2015;10(7):e0133922.

20.

Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1.

Wang C, Hong Z, Chen Y.

Neurochem Res. 2015 Jul;40(7):1546-53. doi: 10.1007/s11064-015-1617-y. Epub 2015 Jun 20.

Items per page

Supplemental Content

Write to the Help Desk